Dr. Frank Mathias to Become CEO of Rentschler Biotechnologie
News Jan 08, 2016
Rentschler Biotechnologie has announced the appointment of Dr. Frank Mathias as Chief Executive Officer (CEO) effective 1 April 2016. Dr. Mathias had previously been a Member of the Supervisory Board at Rentschler.
Former CEO, Dr. Nikolaus F. Rentschler, is moving to the Supervisory Board to concentrate on the further expansion of the Rentschler group.
Dr. Frank Mathias studied pharmacy at the Paris VI University where he graduated in 1991. He has gained more than 25 years’ experience in leading positions in the pharmaceutical and biotech industry. His industrial career began when he assumed a position as international product manager at Hoechst AG.
After that, he became CEO of the successful and reknowned companies Servier Deutschland and Amgen Deutschland. In 2009 he became CEO at Medigene AG where he had formerly taken responsibility for Marketing, Sales and Business Development as CEO. Since then, the company has developed and established further in Immuno-Oncology.
As Chairman of vfa-bio, the stakeholders of biotechnology within vfa Research Based Pharmaceutical Companies, Dr. Mathias maintains excellent contacts within the pharmaceutical and biotech industry.
Dr. Nikolaus F. Rentschler: “We are glad to have been able to take on such an experienced and successful CEO for Rentschler Biotechnologie. He is an expert in this business and has been familiar with the company’s topics for years. The shareholder, Members of the Supervisory Board and Management Board are looking forward to the cooperation.”
Dr. Frank Mathias: “I am impressed by the dynamics and the strong commitment of the leaders and staff of this growing company. On this basis and owing to continuously positive developments on the market we will jointly lead Rentschler Biotechnologie to future success.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE